Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
SAN RAMON, Calif., Feb. 02, 2016 -- SteadyMed Ltd. (Nasdaq:STDY), a pre-NDA stage specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan Rigby, President and Chief Executive Officer will present at the BIO CEO conference on Tuesday, February 9, 2016. Mr. Rigby will provide an overview of the company’s business including its lead drug product candidate Trevyent; a combination of the company’s PatchPump and treprostinil for the treatment of Pulmonary Arterial Hypertension (PAH).
Date: February 9, 2016
Time: 8:30-9:00 am ET
Location: New York, NY
A live audio webcast and archive of the presentation will be available through the Events and Presentations page of the company's corporate website (www.steadymed.com).
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed intends to file an NDA for Trevyent in Q3 2016 and will commercialize Trevyent in the U.S. SteadyMed has licensed certain rights to Cardiome Pharma Corp. for the development and commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
CONTACT: Marylyn Rigby Director, Investor Relations and Marketing 925-272-4999 [email protected]
